Focused on muscle and
positioned for growth

Investors & Media

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCEā„¢ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

Stock information

Stock is

Data Provided by Refinitiv.

Minimum 15 minutes delayed.

Upcoming events

No events scheduled

btn Events

Investor contact

Contact Dyne investor relations at